Brainstorm Cell Therapeutics (BCLI) Tops Q3 EPS by 5c; Reports Cash and Cash Equivalents of $28M
Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q3 EPS of ($0.15), $0.05 better than the analyst estimate of ($0.20).
For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.